Association Study of Energy Homeostasis Genes and Antipsychotic-Induced Weight Gain in Patients with Schizophrenia

Abstract

Introduction: Marked inter-individual variation has been observed with respect to the risk of weight gain and related metabolic disturbances during antipsychotic treatment, which in part could be explained by heritability. Such adverse effects have been proposed to occur through drug-induced mechanisms involving both the central nervous system and different peripheral tissues.

Methods: We genotyped tagSNPs in several genes (ADIPOQ, PRKAA1, PRKAA2, PRKAB1, PRKAG1, PRKAG2, PRKAG3, FTO and FABP3) that regulate lipid and energy homeostasis for their possible association to antipsychotic-induced weight gain.

Results: In a sample of 160 patients of German origin with schizophrenia who had been monitored with respect to body weight, we found marked association between antipsychotic-related changes in BMI and 6 markers in the adiponectin gene (ADIPOQ).

Discussion: These findings support previous observations (in patients’ serum) that adiponectin is involved in antipsychotic-mediated metabolic adverse effects.

References

• 1 Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature.  J Clin Psychiatry. 2001;  62 (S 07) 22-31
• 2 Andersson U, Filipsson K, Abbott CR. et al . AMP-activated protein kinase plays a role in the control of food intake.  J Biol Chem. 2004;  279 12005-12008
• 3 Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research.  Mol Psychiatry. 2007;  12 707-747
• 4 Bai YM, Chen JY, Yang WS. et al . Adiponectin as a potential biomarker for the metabolic syndrome in Chinese patients taking clozapine for schizophrenia.  J Clin Psychiatry. 2007;  68 1834-1839
• 5 Bai YM, Chen TT, Yang WS. et al . Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: a cohort study.  Schizophr Res. 2009;  111 1-8
• 6 Bai YM, Lin CC, Chen JY. et al . Association of initial antipsychotic response to clozapine and long-term weight gain.  Am J Psychiatry. 2006;  163 1276-1279
• 7 Basile VS, Masellis M, De Luca V. et al . 759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain.  Lancet. 2002;  360 1790-1791
• 8 Birkenaes AB, Birkeland KI, Friis S. et al . Hormonal markers of metabolic dysregulation in patients with severe mental disorders after olanzapine treatment under real-life conditions.  J Clin Psychopharmacol. 2009;  29 109-116
• 9 Carling D. The AMP-activated protein kinase cascade – a unifying system for energy control.  Trends Biochem Sci. 2004;  29 18-24
• 10 Cheung PC, Salt IP, Davies SP. et al . Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role in AMP binding.  Biochem J. 2000;  346 (Pt 3) 659-669
• 11 Correll CU, Malhotra AK. Pharmacogenetics of antipsychotic-induced weight gain.  Psychopharmacology (Berl). 2004;  174 477-489
• 12 Ellingrod VL, Perry PJ, Ringold JC. et al . Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine.  Am J Med Genet B Neuropsychiatr Genet. 2005;  134B 76-78
• 13 Ferno J, Raeder MB, Vik-Mo AO. et al . Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action?.  Pharmacogenomics J. 2005;  5 298-304
• 14 Ferno J, Skrede S, Vik-Mo AO. et al . Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs.  BMC Neurosci. 2006;  7 69
• 15 Ferno J, Vik-Mo AO, Jassim G. et al . Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver.  Psychopharmacology (Berl). 2009;  203 73-84
• 16 Frayling TM, Timpson NJ, Weedon MN. et al . A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity.  Science. 2007;  316 889-894
• 17 Gregoor JG, van der Weide J, Mulder H. et al . Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication.  J Clin Psychopharmacol. 2009;  29 21-25
• 18 Hardie DG. AMP-activated protein kinase as a drug target.  Annu Rev Pharmacol Toxicol. 2007;  47 185-210
• 19 Heid IM, Henneman P, Hicks A. et al . Clear detection of ADIPOQ locus as the major gene for plasma adiponectin: results of genome-wide association analyses including 4 659 European individuals.  Atherosclerosis. 2010;  208 412-420
• 20 Hivert MF, Manning AK, McAteer JB. et al . Common variants in the adiponectin gene (ADIPOQ) associated with plasma adiponectin levels, type 2 diabetes, and diabetes-related quantitative traits: the Framingham Offspring Study.  Diabetes. 2008;  57 3353-3359
• 21 Juutinen J, Hakko H, Meyer-Rochow VB. et al . Body mass index (BMI) of drug-naive psychotic adolescents based on a population of adolescent psychiatric inpatients.  Eur Psychiatry. 2008;  23 521-526
• 22 Kadowaki T, Yamauchi T, Kubota N. et al . Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome.  J Clin Invest. 2006;  116 1784-1792
• 23 Kahn BB, Alquier T, Carling D. et al . AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism.  Cell Metab. 2005;  1 15-25
• 24 Kang SG, Lee HJ, Park YM. et al . Possible association between the −2548A/G polymorphism of the leptin gene and olanzapine-induced weight gain.  Prog Neuropsychopharmacol Biol Psychiatry. 2008;  32 160-163
• 25 Kim SF, Huang AS, Snowman AM. et al . Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.  PNAS. 2007;  104 3456-3459
• 26 Le Hellard S, Theisen FM, Haberhausen M. et al . Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects?.  Mol Psychiatry. 2009;  14 308-317
• 27 Leucht S, Corves C, Arbter D. et al . Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis.  Lancet. 2009;  373 31-41
• 28 Lieberman JA, Stroup TS, McEvoy JP. et al . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.  N Engl J Med. 2005;  353 1209-1223
• 29 Lopez M, Lage R, Saha AK. et al . Hypothalamic fatty acid metabolism mediates the orexigenic action of ghrelin.  Cell Metab. 2008;  7 389-399
• 30 Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications.  Drugs. 2004;  64 701-723
• 31 Miller DD, Ellingrod VL, Holman TL. et al . Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism.  Am J Med Genet B Neuropsychiatr Genet. 2005;  133B 97-100
• 32 Minokoshi Y, Alquier T, Furukawa N. et al . AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus.  Nature. 2004;  428 569-574
• 33 Opgen-Rhein C, Brandl EJ, Muller DJ. et al . Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample.  Pharmacogenomics. 2010;  11 773-780
• 34 Raeder MB, Ferno J, Vik-Mo AO. et al . SREBP activation by antipsychotic- and antidepressant-drugs in cultured human liver cells: relevance for metabolic side-effects?.  Mol Cell Biochem. 2006;  289 167-173
• 35 Reynolds GP, Zhang Z, Zhang X. Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain.  Am J Psychiatry. 2003;  160 677-679
• 36 Reynolds GP, Zhang ZJ, Zhang XB. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism.  Lancet. 2002;  359 2086-2087
• 37 Templeman LA, Reynolds GP, Arranz B. et al . Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis.  Pharmacogenet Genomics. 2005;  15 195-200
• 38 Thakore JH, Mann JN, Vlahos I. et al . Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia.  Int J Obes Relat Metab Disord. 2002;  26 137-141
• 39 Theisen FM, Hinney A, Bromel T. et al . Lack of association between the −759C/T polymorphism of the 5-HT2C receptor gene and clozapine-induced weight gain among German schizophrenic individuals.  Psychiatr Genet. 2004;  14 139-142
• 40 Tiwari AK, Zai CC, Meltzer HY. et al . Association study of polymorphisms in Insulin Induced Gene 2 (INSIG2) with antipsychotic-induced weight gain in European and African-American schizophrenia patients.  Hum Psychopharmacol. 2010;  25 253-259
• 41 Verma SK, Subramaniam M, Liew A. et al . Metabolic risk factors in drug-naive patients with first-episode psychosis.  J Clin Psychiatry. 2009;  70 997-1000
• 42 Yamauchi T, Kamon J, Minokoshi Y. et al . Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase.  Nat Med. 2002;  8 1288-1295
• 43 Zhang XY, Tan YL, Zhou DF. et al . Association of clozapine-induced weight gain with a polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese population.  J Clin Psychopharmacol. 2007;  27 246-251
• 44 Zhang ZJ, Yao ZJ, Mou XD. et al . Association of -2548G/A functional polymorphism in the promoter region of leptin gene with antipsychotic agent-induced weight gain.  Zhonghua Yi Xue Za Zhi. 2003;  83 2119-2123

Correspondence